Market capitalization | $1.60b |
Enterprise Value | $593.11m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 56.01 |
P/S ratio (TTM) P/S ratio | 150.64 |
P/B ratio (TTM) P/B ratio | 1.56 |
Revenue growth (TTM) Revenue growth | 30.99% |
Revenue (TTM) Revenue | $10.59m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
15 Analysts have issued a Janux Therapeutics Inc forecast:
15 Analysts have issued a Janux Therapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 11 11 |
31%
31%
|
|
Gross Profit | 8.53 8.53 |
39%
39%
|
|
EBITDA | -97 -97 |
36%
36%
|
EBIT (Operating Income) EBIT | -99 -99 |
35%
35%
|
Net Profit | -69 -69 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.
Head office | United States |
CEO | David Campbell |
Employees | 81 |
Founded | 2017 |
Website | www.januxrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.